Navigation Links
New needle-free HPV vaccine increases effectiveness, availability in developing world
Date:11/17/2010

Arlington, Va. New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.

HPV is the number one cause of cervical cancer, which is the second most common cancer in women around the globe. According to the World Health Organization, nearly a quarter of a million women die each year from cervical cancer, 80 percent of them in developing countries.

Lead researcher David McAdams and colleagues from the University of Colorado at Boulder created a dry powder that goes directly to the mucous membranes in the respiratory tract or mouth. Since HPV is a disease that affects the mucous membranes, the powder is more targeted. "Imagine the vaccine as a car," said McAdams. "Using this delivery method is similar to parking in your driveway instead of driving around the block a few times to find a spot."

The dry powder has added benefits for developing countries. For example, the current HPV vaccine is delivered by a needle injection, which is highly susceptible to contamination. The powder, as a solid, rather than a frozen liquid, may be more stable than current HPV vaccines, which makes it easier to store and transport in developing countries.

"While there are effective HPV vaccines on the market, cost, refrigeration and needle disposal shorten the reach they have," commented McAdams. "Our goal is to develop an economical, safe and easily administered HPV vaccine for everyone."

For the first time, FIP's PSWC and the AAPS Annual Meeting and Exposition will join to hold the world's largest pharmaceutical sciences meeting to improve global health through advances in pharmaceutical sciences. An estimated 10,000 scientists from more than 60 countries will participate in 100 sessions, including 40 symposia and roundtables.


'/>"/>

Contact: Joseph Catapano
catapanoJ@aaps.org
703-248-4772
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related biology news :

1. New low-cost method to deliver vaccine shows promise
2. Consortium to design human trials of mosaic HIV vaccine
3. Cow vaccines go vroom
4. Doctors not strongly encouraging HPV vaccine to girls of certain age
5. Scientists use computer algorithms to develop seasonal flu vaccines
6. 2009 H1N1 vaccine protects against 1918 influenza virus
7. New discovery could aid development of elusive bovine mastitis vaccine
8. New bacterial signaling molecule could lead to improved vaccines
9. MSU researchers testing vaccine to help people quit smoking
10. New steps toward a universal flu vaccine
11. Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology: